<DOC>
	<DOCNO>NCT02976857</DOCNO>
	<brief_summary>The trial single arm , single-center , non-randomized phase I clinical trial design evaluate safety efficacy C-CAR011 treatment refractory DLBCL</brief_summary>
	<brief_title>A Phase 1 Study Evaluating Safety Efficacy C-CAR011 Treatment DLBCL Subjects</brief_title>
	<detailed_description>The 3x3 dose escalation design adopt order determine maximum tolerate dose ( MTD ) . Subjects enrol low-dose group , medium-dose group high-dose group : Dose CAR+ cells/kg Low 0.8×106 Medium 2.5×106 High 5.0×106 DLT evaluate within 30 day post C-CAR011 infusion ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Histologically diagnose DLBCL accord NCCN nonHodgkin 's lymphoma Clinical Practice Guidelines ( 3rd edition 2016 ) Refractory DLBCL All subject must receive adequate prior therapy include antiCD20 monoclonal antibody ( unless tumor CD20negative ) anthracycline contain chemotherapy regimen . The standardized treatment regimen reference NCCN nonHodgkin lymphoma Clinical Practice Guidelines ( 2016 Version 3 ) At least one measurable lesion per revise IWG Response Criteria ( long diameter tumor ≥ 1.5 cm ) Age 1870 year old , male female Expected survival ≥ 12 week ECOG score 01 Subject 's left ventricular ejection fraction ( LVEF ) ≥ 50 % evidence pericardial effusion determine ECHO At least 4 week receive previous treatment ( radiotherapy , chemotherapy , monoclonal antibody therapy treatment ) No contraindication peripheral blood apheresis Female subject childbearing age , serum urine pregnancy test must negative , must agree take effective contraceptive measure trial measure Volunteered participate study sign inform consent Have history allergy cellular product Used genetically modify T cell therapy History allogeneic hematopoietic stem cell transplantation Severe active infection ( uncomplicated urinary tract infection , bacterial pharyngitis allow ) currently receive intravenous antibiotic therapy receive intravenous antibiotic therapy within one week . Prophylactic antibiotic , antiviral antifungal treatment permissible Hepatitis B hepatitis C virus infection ( include carrier ) , well acquire , congenital immune deficiency disease , include limited HIVinfected person Patients class III IV heart failure accord NYHA Heart Failure Classifications A history QT prolongation A history epilepsy central nervous system disorder The patient history primary cancer , follow exception : Excisional nonmelanoma cutaneous basal cell carcinoma ; Cured situ carcinoma cervical cancer , bladder cancer breast cancer Subjects autoimmune disease immune deficiency disease disease need immunosuppressive therapy Used systemic steroid within two week ( use inhale steroid exception ) Women pregnant lactate breed intent 6 month Participated clinical trial within three month The investigator believe increase risk subject interference result trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>refractory diffuse large B-cell lymphoma</keyword>
	<keyword>anti-CD19 chimeric antigen receptor T-cell</keyword>
</DOC>